Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4–10 ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score
Table 1
Baseline clinical characteristics and univariable analysis of risk factors for presence of PCa and HGPCa.
All
Prostate cancer
High grade prostate cancer
No
Yes
Chi-square or
value
No
Yes
Chi-square or
value
Patients, number (%)
345 (100)
207 (60.0)
138 (40.0)
245 (71.0)
100 (29.0)
PSA, mean ± SD
7.15 ± 1.57
7.16 ± 1.57
−0.126
0.900
7.13 ± 1.57
7.23 ± 1.57
−0.645
0.519
PSA, number (%)
0.124
0.742
0.540
0.477
≦7 nL/mL
159 (46.1)
97 (46.9)
62 (44.9)
116 (47.4)
43 (43.0)
>7 ng/mL
186 (53.9)
110 (53.1)
76 (55.1)
129 (52.6)
57 (57.0)
%fPSA, mean ± SD
0.158 ± 0.065
0.154 ± 0.081
−1.637
0.102
0.159 ± 0.065
0.152 ± 0.087
−2.191
%fPSA, number (%)
7.029
9.511
<0.16
190 (55.1)
102 (49.3)
88 (63.8)
122 (49.8)
68 (68.0)
≧0.16
155 (44.9)
105 (50.7)
50 (36.2)
123 (50.2)
32 (32.0)
PV, mean ± SD
61.89 ± 26.37
47.78 ± 24.07
−5.783
<
60.82 ± 26.85
45.04 ± 21.46
−5.711
<
PV, number (%)
32.664
<
27.955
<
≦50 mL
175 (50.7)
79 (38.2)
96 (69.6)
102 (41.6)
73 (73.0)
>50 mL
170 (49.3)
128 (61.8)
42 (30.4)
143 (58.4)
27 (27.0)
Age, mean ± SD
64.06 ± 9.10
70.74 ± 7.52
−6.836
<
65.16 ± 9.06
70.60 ± 8.03
−5.066
<
Age, number (%)
38.074
<
21.804
<
≤68
185 (53.6)
139 (67.1)
46 (33.3)
151 (61.6)
34 (34.0)
>68
160 (46.4)
68 (32.9)
92 (66.7)
94 (38.4)
66 (66.0)
MRI, number (%)
57.610
<
63.486
<
Negative
132 (38.3)
111 (53.6)
21 (15.2)
121 (49.4)
11 (11.0)
Suspicious
79 (22.9)
44 (21.3)
35 (25.4)
60 (24.5)
19 (19.0)
Positive
134 (38.8)
52 (25.1)
82 (59.4)
64 (26.1)
70 (70.0)
DRE, number (%)
12.933
<
17.297
<
Unsuspicious
292 (84.6)
187 (90.3)
105 (76.1)
220 (89.8)
72 (72.0)
Suspicious
53 (15.4)
20 (9.7)
33 (23.9)
25 (10.2)
28 (28.0)
Smoke, number (%)
0.004
0.953
0.236
0.627
Absent
288 (83.5)
173 (83.6)
115 (83.3)
203 (82.9)
85 (85.0)
Present
57 (16.5)
34 (16.4)
23 (16.7)
42 (17.1)
15 (15.0)
Statistically significant. PCa = prostate cancer; HGPCa = high grade prostate cancer; PSA = prostate specific antigen; %fPSA = percentage of free PSA; PV = prostate volume; MRI = magnetic resonance imaging; DRE = digital rectal examination.
